Clinical trials: Acquired Immune Deficiency Syndrome
HIV Infections
A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)
The objectives of this study are: To establish whether there is a difference in clinical effectiveness of Liposyn II 20 percent as compared with Liposyn III 2 percent in AIDS patients with Pneumocystis carinii pneumonia (PCP).
- Trial name
- NCT00002275
- Testing
- Fat Emulsion 2%, Fat Emulsion 20%
- Where
- United States
- Sponsor
- Abbott
AIDS
Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc
The objective of this study was to estimate the effects of a single dose of vardenafil on the blood pressure (BP) in subjects receiving maraviroc (MVC) (dosed to steady-state) and to assess the safety and tolerability of MVC in…
- Trial name
- NCT00853840
- Testing
- Maraviroc, Vardenafil
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Cytomegalovirus Retinitis, HIV Infections
A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis
To determine the safety and tolerance of 3 dosage levels of human anti-cytomegalovirus (CMV) monoclonal antibody (SDZ MSL-109) when administered once every 2 weeks for a total of 8 doses during the maintenance phase of…
- Trial name
- NCT00002016
- Testing
- Sevirumab
- Where
- 2 sites in United States
- Sponsor
- Sandoz
HIV Infections
A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons
To examine the continued safety and tolerability of four doses of vesnarinone in HIV-infected patients who have completed a short-term study (less than 12 months on continuous treatment) of the drug.
- Trial name
- NCT00002130
- Testing
- Vesnarinone
- Where
- 2 sites in United States
- Sponsor
- Otsuka America Pharmaceutical
HIV-1-infection
Comparative Study of PK and BE of VM-1500FDC (Fixed-dose Combination) and Elpida® With Truvada® сo-administrated 1 Daily Fasting in Healthy Subjects
Open-label, randomized, parallel-group, comparative study of pharmacokinetics and bioequivalence of VM-1500FDC (elsulfavirine/emtricitabine/tenofovir fixed-dose combination) and Elpida® with Truvada® (emtricitabine/tenofovir)…
- Trial name
- NCT03706924
- Testing
- VM-1500FDC, Elpida®, Truvada®
- Where
- 2 sites in Russia
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Viriom
HIV Infections
Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine
To compare the efficacy and safety of orally administered didanosine (ddI) with orally administered zidovudine (AZT) in the treatment of patients who exhibit increasing clinical deterioration despite treatment with AZT.
- Trial name
- NCT00002035
- Testing
- Zidovudine, Didanosine
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Bristol-Myers Squibb
Human Immunodeficiency Virus
Kaletra: Therapy With Double Protease Inhibitors
Therapy with lopinavir/ritonavir (Kaletra) and one other protease inhibitor in Human Immunodeficiency Virus participants
- Trial name
- NCT01075191
- Where
- 17 sites in Germany
- Volunteers
- 65 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HIV Infections
Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)
This study will test the safety and immunogenicity of an investigational Human Immunodeficiency Virus (HIV) vaccine. Immunogenicity will be measured by evaluating the immune response to several different dose levels.
- Trial name
- NCT00350623
- Testing
- MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520), MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520), MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Subjects, Infection, Human Immunodeficiency Virus
GSK1349572 Drug Interaction Study With Protease Inhibitors
A study in healthy volunteers to determine whether there is a drug interaction between GSK1349572 and the HIV protease inhibitors lopinavir/ritonavir and darunavir/ritonavir
- Trial name
- NCT00774735
- Testing
- GSK1349572
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
AIDS
Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose
The purpose of this study is to evaluate the safety and reactogenicity of one booster dose of a HIV candidate vaccine after administration of one oral dose of chloroquine.
- Trial name
- NCT00972725
- Testing
- GSK Biologicals' HIV vaccine (732461), Chloroquine
- Where
- Belgium
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sarcoma, Kaposi, HIV Infections
Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.
To provide Stealth liposomal doxorubicin hydrochloride ( DOX-SL ) as a therapy for Kaposi's sarcoma patients who have no remaining treatment options other than DOX-SL or patients who have been participating in another DOX-SL…
- Trial name
- NCT00002147
- Testing
- Doxorubicin hydrochloride (liposomal)
- Where
- United States
- Sponsor
- Sequus Pharmaceuticals
Neuropathy, AIDS
Safety and Preliminary Evidence of Efficacy of Escalating Doses of Dimiracetam in AIDS Patients With Painful Neuropathy
One hundred consenting AIDS patients suffering from treatment induced painful neuropathy will be blindly randomize to Active and Placebo groups (ratio A/P = 3/2 and will receive increasing oral doses of dimiracetam starting from…
- Trial name
- NCT01135251
- Testing
- dimiracetam, sugar pill
- Where
- South Africa
- Volunteers
- 116 people
- Sponsor
- Neurotune AG
Cytomegalovirus Retinitis, HIV Infections
An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients
To evaluate the safety and efficacy of foscarnet induction therapy for treatment of AIDS patients experiencing their first episode of cytomegalovirus (CMV) retinitis.
- Trial name
- NCT00002039
- Testing
- Foscarnet sodium
- Where
- United States
- Sponsor
- Astra USA
Infection, Human Immunodeficiency Virus
Dolutegravir Renal Impairment Study
Dolutegravir (DTG, GSK1349572) is an integrase inhibitor being developed for the treatment of human immunodeficiency virus (HIV)-1 infection by GlaxoSmithKline (GSK) on behalf of Shionogi-ViiV Healthcare LLC.
- Trial name
- NCT01353716
- Testing
- Dolutegravir 50 mg
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus
Study of Dapivirine Vaginal Ring (VR) in Adolescents
To assess the safety of dapivirine (25 mg) administered via a silicone vaginal ring in HIV-uninfected adolescent females, when inserted once every 4 weeks during 24-week of study product use.
- Trial name
- NCT02028338
- Testing
- dapivirine ring
- Where
- 11 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
HIV Infection, Infection, Human Immunodeficiency Virus
A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.
This study is a two-part study. Part one is designed to see how different formulations of GSK364735 are absorbed in the body and To see how food affects how GSK364735 is absorbed in the body.
- Trial name
- NCT00386347
- Testing
- GSK364735 oral solution and oral tablets
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Immunodeficiency Virus
Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients
To demonstrate that patients treated with Kaletra have an improvement in their quality of life compared to the quality of life they had with their previous NRTI therapy.
- Trial name
- NCT00648999
- Testing
- lopinavir/ritonavir
- Where
- 13 sites in Mexico
- Volunteers
- 207 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HIV Infections
A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients
To determine the MTD and dose-limiting toxicities of recombinant interleukin-2 (aldesleukin; Proleukin) administered subcutaneously in HIV-seropositive patients.
- Trial name
- NCT00002107
- Testing
- Aldesleukin
- Where
- United States
- Sponsor
- Chiron Corporation
HIV Infections
GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers
This study is a Phase 1, double-blind (sponsor-unblinded), randomized, placebo-controlled, single- and repeat-dose escalation study including a weekly oral dose (MAD) cohort and a relative bioavailability (RBA) and food effect…
- Trial name
- NCT04493684
- Testing
- GSK3739937 (PIB), GSK3739937 (Tablet)
- Where
- United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections, AIDS
DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy
The purpose of this study is to evaluate whether a therapy with an all once daily regimen of stavudine extended release (d4T XR), lamivudine (3TC), and efavirenz (EFV) leads to improved outcomes, as measured by viral load, CD4…
- Trial name
- NCT00116116
- Testing
- efavirenz, stavudine extended release, lamivudine
- Where
- 10 sites in United States
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb